Eleanor and Lou Gehrig ALS Center at Columbia University

Eleanor and Lou Gehrig ALS Center at Columbia University Columbia University's Comprehensive ALS Clinical Care and Research Center

Addressing the Complex Needs of Patients with Amyotrophic Lateral Sclerosis

Proud of our work to develop this A*O for FUS-ALS patients and families, and so happy for Jeff and his family. The glob...
04/05/2026

Proud of our work to develop this A*O for FUS-ALS patients and families, and so happy for Jeff and his family. The global phase 3 trial of this antisense drug is fully enrolled, with top-line results anticipated later this year.

Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a mutated gene that made it likely he would develop ALS.

Experimental treatments brings hope to ALS patients - CBS News
04/04/2026

Experimental treatments brings hope to ALS patients - CBS News

"CBS Saturday Morning" looks at an experimental treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, that is bringing hope to some patients suffering from the neurodegenerative disease. To inquire about possible participation in Silence ALS, an initiative to develop individualized g...

Jeff's Story: Defying a Family History of ALS
11/30/2025

Jeff's Story: Defying a Family History of ALS

After losing several family members to a rare, inherited form of ALS, Jeff remains symptom-free thanks to a groundbreaking clinical trial at Columbia.

Silence ALS is a collaborative effort between Columbia University's Eleanor and Lou Gehrig ALS Center at Columbia Univer...
03/22/2024

Silence ALS is a collaborative effort between Columbia University's Eleanor and Lou Gehrig ALS Center at Columbia University and the n-Lorem Foundation.

The research aims to help an underserved portion of ALS patients by creating customized therapies.

FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS
05/16/2023

FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS

Though limited to patients with a rare genetic mutation, the newest drug for ALS could be most effective when given before symptoms emerge.

Anna's Story of Hope and HelpIn this episode, Stan talks with Sonja and Dr. Neil Shneider, associate professor of motor ...
09/03/2022

Anna's Story of Hope and Help

In this episode, Stan talks with Sonja and Dr. Neil Shneider, associate professor of motor neuron disorders at Columbia Medical School, about Sonja’s daughter, Anna. She is 17 years old and suffers an aggressive, fatal form of ALS.

Quickly and easily listen and subscribe to Patient Empowerment Program: A Rare Disease Podcast for free in your podcast app of choice.

We are so pleased and proud to be part of this extraordinary experience. What a strong and courageous young woman you ar...
07/15/2022

We are so pleased and proud to be part of this extraordinary experience. What a strong and courageous young woman you are, Anna.

+-+-+-+-+ BREAKING NEWS +-+-+-+-+Hallo zusammen, nachdem ich nun die offizielle Freigabe habe, möchte ich Euch das nicht länger vorenthalten. Neben Tofersen ...

Address

710 W 168th Street
New York, NY
10032

Telephone

+12123056788

Website

Alerts

Be the first to know and let us send you an email when Eleanor and Lou Gehrig ALS Center at Columbia University posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Eleanor and Lou Gehrig ALS Center at Columbia University:

Shortcuts

Share

Category